SCHEMBL14732174

SCHEMBL14732174

CCn1c(CNc2ccc(C)c(Cl)c2)nnc1SCC(=O)Nc1cccc2ccccc12

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.63
▸ KMT2A Q03164 2/20 0.56
▸ PTGES O14684 1/20 0.56
▸ MEN1 O00255 1/20 0.56
▸ MAPT P10636 3/20 0.55
▸ ALDH1A1 P00352 4/20 0.54
▸ MAPK1 P28482 2/20 0.54
▸ SLC27A1 Q6PCB7 5/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ RORC P51449 1/20 0.54
▸ LMNA P02545 1/20 0.54
▸ GAA P10253 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ USP2 O75604 1/20 0.53
▸ ALOX15 P16050 1/20 0.53
▸ TSHR P16473 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19368234 0.90 MAPT (0.64) SMN1; SMN2KMT2APTGESMEN1MAPT
SCHEMBL14732159 0.89 SMN1; SMN2 (0.67) SMN1; SMN2KMT2APTGESMEN1MAPT
SCHEMBL14732156 0.89 SMN1; SMN2 (0.63) SMN1; SMN2KMT2AMEN1MAPTALDH1A1
SCHEMBL14732106 0.84 SMN1; SMN2 (0.61) SMN1; SMN2KMT2AMEN1MAPTALDH1A1
SCHEMBL14732084 0.79 L3MBTL1 (0.62) SMN1; SMN2PTGESMAPTALDH1A1MAPK1
SCHEMBL14732175 0.78 KMT2A (0.43) SMN1; SMN2KMT2APTGESMEN1MAPT
SCHEMBL18559373 0.78 SMN1; SMN2 (1.00) SMN1; SMN2KMT2AMAPTALDH1A1CYP3A4
SCHEMBL13832073 0.76 MEN1 (0.69) SMN1; SMN2KMT2AMEN1ALDH1A1MAPK1
SCHEMBL4208962 0.74 PTGES (0.58) KMT2APTGESMEN1MAPTALDH1A1
SCHEMBL13831958 0.73 CYP3A4 (0.65) SMN1; SMN2KMT2AMEN1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180258133-A1 MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA ORPHAGEN PHARMACEUTICALS INC (US) 2018-09-13 — — US disclosed
US-20170267712-A1 MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA ORPHAGEN PHARMACEUTICALS INC (US) 2017-09-21 — — US disclosed
US-9657053-B2 Modulators of retinoid-related orphan receptor gamma Orphagen Pharmaceuticals (US) 2017-05-23 — — US disclosed
US-9657053-B2 Modulators of retinoid-related orphan receptor gamma Orphagen Pharmaceuticals (US) 2017-05-23 — — US disclosed
US-20130150333-A1 MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA Orphagen Pharmaceuticals (US) 2013-06-13 — — US disclosed
US-20130150333-A1 MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA Orphagen Pharmaceuticals (US) 2013-06-13 — — US disclosed
US-8389739-B1 Modulators of retinoid-related orphan receptor gamma Orphagen Pharmaceuticals (US) 2013-03-05 — — US disclosed
US-8389739-B1 Modulators of retinoid-related orphan receptor gamma Orphagen Pharmaceuticals (US) 2013-03-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180258133-A1 MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA RORC, RORB, RORA SMN1; SMN2 3335/4885KMT2A 3188/4885PTGES 633/4885
US-20130150333-A1 MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA RORC, RORB, RORA SMN1; SMN2 3335/4885KMT2A 3188/4885PTGES 633/4885
US-20170267712-A1 MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA RORC, RORB, RORA SMN1; SMN2 3335/4885KMT2A 3188/4885PTGES 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback